Alaunos Therapeutics (NASDAQ:TCRT) Issues Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) issued its quarterly earnings results on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.00 million during the quarter.

Alaunos Therapeutics Stock Up 1.4%

Shares of NASDAQ:TCRT traded up $0.04 during midday trading on Tuesday, hitting $2.86. The stock had a trading volume of 50,095 shares, compared to its average volume of 15,862. The company’s 50-day moving average price is $2.96 and its 200-day moving average price is $3.06. The company has a market capitalization of $6.64 million, a P/E ratio of -1.24 and a beta of -1.29. Alaunos Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $6.20.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Alaunos Therapeutics has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alaunos Therapeutics stock. Geode Capital Management LLC raised its position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,736 shares of the company’s stock after purchasing an additional 3,945 shares during the period. Geode Capital Management LLC owned approximately 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent reporting period. 27.72% of the stock is owned by institutional investors.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.